The Role of MNX1–AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA–RNA Interactions
International Journal of Molecular Sciences · 11.04.2026 · 27 (8) · 3428
DOI: 10.3390/ijms27083428 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.04.2026. Verfasst von Alvaro Gutierrez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Uni…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, RNA, Long Noncoding, Transcription Factors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Funding for Scientific and Technologic Development of Chile, National Agency for Research and Development, Dirección de Investigación de Universidad de La Frontera.
Abstract (Originalsprache)
Ovarian cancer (OC) remains one of the deadliest gynecological malignancies, largely due to late diagnosis and the emergence of resistance to platinum–based chemotherapy. Long non–coding RNAs (lncRNAs) have recently emerged as key regulators of tumor progression and therapeutic adaptation. In this study, we performed integrative transcriptomic profiling of patient–derived TCGA ovarian tumor samples and carboplatin–resistant A2780 (CBDCA–R–A2780) cells to identify lncRNAs whose dysregulation overlaps between a cell–line resistance model and patient tumors. Our analyses revealed extensive transcriptional remodeling across both datasets, with MNX1–AS1 consistently emerging as a strongly deregulated transcript. Differential expression analysis showed robust upregulation of MNX1–AS1 in resistant cells and tumor tissues, accompanied by correlations with epithelial–mesenchymal transition (EMT)–related transcription factors such as FOXA1 and SNAI2 and inverse associations with epithelial markers including CDH1. Computational predictions using RIblast identified specific MNX1–AS1 binding regions with candidate miRNAs and mRNAs, prioritizing EMT–related transcripts (e.g., SNAI2, FOXA1, ZEB1) with favorable hybridization energies for future validation. Additional prioritized interactors included genes linked to stress response (IER2, FOSB) and invasion (MMP11, MMP1). Because A2780 has been discussed as an endometrioid–like/non–serous ovarian cancer model, mechanistic inferences primarily apply to this in vitro context, while TCGA analyses provide associative support rather than mechanistic validation. Collectively, these findings highlight MNX1–AS1 as a candidate regulator associated with transcriptional reprogramming in OC and a promising prognostic biomarker warranting further functional testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.
- Millenium Institute of Immunology and Immunotherapy, Santiago 8331150, Chile.
- Programa de Doctorado en Ciencias, Mención Biología Celular y Molecular Aplicada, Universidad de La Frontera, Temuco 4811230, Chile.
- Programa de Doctorado en Ciencias de Recursos Naturales, Universidad de La Frontera, Temuco 4811230, Chile.
- Departamento de Ciencias Básicas, Facultad de Medicina. Universidad de La Frontera, Temuco 4810296, Chile.
- Facultad de Ciencias, Universidad San Sebastián, Valdivia 5110246, Chile.
ORCID-Profile: Rodrigo Maldonado, Juan Machuca, Carmen Gloria Ili, Priscilla Brebi, Kurt Buchegger, Tamara Viscarra
Förderung
- National Funding for Scientific and Technologic Development of Chile
- National Agency for Research and Development
- Dirección de Investigación de Universidad de La Frontera
- Millennium Institute on Immunology and Immunotherapy
Zitieren
APA
Gutierrez, A., Larronde, C., Silva, S., Castro, C., Maldonado, R., León, D., Machuca, J., Ili, C. G., Brebi, P., Buchegger, K., & Viscarra, T. (2026). The Role of MNX1–AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA–RNA Interactions. International Journal of Molecular Sciences, 27(8), 3428. https://doi.org/10.3390/ijms27083428
Vancouver
Gutierrez A, Larronde C, Silva S, Castro C, Maldonado R, León D, et al. The Role of MNX1–AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA–RNA Interactions. International Journal of Molecular Sciences. 2026;27(8):3428. doi:10.3390/ijms27083428
BibTeX
@article{Gutierrez2026,
author = {Gutierrez, Alvaro and Larronde, Carolina and Silva, Salomé and Castro, Constanza and Maldonado, Rodrigo and León, Daniela and Machuca, Juan and Ili, Carmen Gloria and Brebi, Priscilla and Buchegger, Kurt and Viscarra, Tamara},
title = {The Role of MNX1–AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA–RNA Interactions},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3428},
doi = {10.3390/ijms27083428}
}
EUVIMED